Xiaorong Dong

机构：Lanzhou University Second Hospital, Wuhan Union Hospital, Union Hospital, Lanzhou University · ORCID：0000-0001-7470-1836

发表论文 259 篇 · 总被引 5473 次 · h-index 41

代表论文

• Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer (2025 · New England Journal of Medicine · 被引 53)
• SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced HER2 -mutant non-small cell lung cancer (NSCLC) who were pretreated but naïve to HER2-targeted therapy or had not received any treatment for advanced disease. (2025 · Journal of Clinical Oncology · 被引 8)
• Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study (2025 · Signal Transduction and Targeted Therapy · 被引 7)
• Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study (2025 · European Journal of Cancer · 被引 3)
• Intrathecal pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: a clinical efficacy and multiplex liquid proteomics exploration study (2025 · The Oncologist · 被引 3)
• Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLC (2025 · iScience · 被引 3)